SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35139340.
- Also identified by DOI 10.1016/j.cell.2022.01.015 and PMC identifier 8784649.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We address whether T cell responses induced by different vaccine platforms (mRNA-1273, BNT162b2, Ad26.COV2.S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 variants. T cell responses to early variants were preserved across vaccine platforms. By contrast, significant overall decreases were observed for memory B cells and neutralizing antibodies. In subjects ∼6 months post-vaccination, 90% (CD4<sup>+</sup>) and 87% (CD8<sup>+</sup>) of memory T cell responses were preserved against variants on average by AIM assay, and 84% (CD4<sup>+</sup>) and 85% (CD8<sup>+</sup>) preserved against Omicron. Omicron RBD memory B cell recognition was substantially reduced to 42% compared with other variants. T cell epitope repertoire analysis revealed a median of 11 and 10 spike epitopes recognized by CD4<sup>+</sup> and CD8<sup>+</sup> T cells, with average preservation > 80% for Omicron. Functional preservation of the majority of T cell responses may play an important role as a second-level defense against diverse variants.
Medical subject headings
- COVID-19 Vaccines
- Memory B Cells
- Memory T Cells
- SARS-CoV-2